生产企业：Revolution Medicines
Daraxonrasib (RMC-6236) is an investigational targeted therapy that nearly doubled survival in a Phase 3 clinical trial for metastatic pancreatic cancer, increasing median survival from 6.7 months to 13.2 months and reducing the risk of death by 60%.
Daraxonrasib (RMC-6236) is an investigational targeted therapy that nearly doubled survival in a Phase 3 clinical trial for metastatic pancreatic cancer, increasing median survival from 6.7 months to 13.2 months and reducing the risk of death by 60%.
Oral, direct RAS(ON) multi-selective (pan-RAS) small-molecule inhibitor: targets GTP-bound (active) mutant and wild-type RAS, blocking active-state RAS signaling across a broad range of cancers driven by oncogenic RAS.
Metastatic pancreatic cancer
共 1 项相关疾病
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
